Agios Pharmaceuticals Inc (NASDAQ: AGIO)’s stock price has plunge by -8.23relation to previous closing price of 39.02. Nevertheless, the company has seen a -6.18% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-18 that CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the designation of mitapivat, an oral, small molecule PK activator, as an orphan medicinal product (OMP) for the treatment of sickle cell disease. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.
Is It Worth Investing in Agios Pharmaceuticals Inc (NASDAQ: AGIO) Right Now?
Agios Pharmaceuticals Inc (NASDAQ: AGIO) has a higher price-to-earnings ratio of 3.15x compared to its average ratio. AGIO has 36-month beta value of 0.85. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AGIO is 55.14M, and currently, short sellers hold a 8.29% ratio of that float. The average trading volume of AGIO on December 20, 2024 was 759.27K shares.
AGIO’s Market Performance
The stock of Agios Pharmaceuticals Inc (AGIO) has seen a -6.18% decrease in the past week, with a -34.18% drop in the past month, and a -23.07% fall in the past quarter. The volatility ratio for the week is 9.85%, and the volatility levels for the past 30 days are at 7.80% for AGIO. The simple moving average for the last 20 days is -29.67% for AGIO stock, with a simple moving average of -15.03% for the last 200 days.
Analysts’ Opinion of AGIO
Raymond James, on the other hand, stated in their research note that they expect to see AGIO reach a price target of $51. The rating they have provided for AGIO stocks is “Outperform” according to the report published on October 10th, 2024.
Leerink Partners gave a rating of “Market Perform” to AGIO, setting the target price at $56 in the report published on September 27th of the current year.
AGIO Trading at -27.80% from the 50-Day Moving Average
After a stumble in the market that brought AGIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.78% of loss for the given period.
Volatility was left at 7.80%, however, over the last 30 days, the volatility rate increased by 9.85%, as shares sank -34.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.42% lower at present.
During the last 5 trading sessions, AGIO fell by -6.18%, which changed the moving average for the period of 200-days by +12.65% in comparison to the 20-day moving average, which settled at $50.92. In addition, Agios Pharmaceuticals Inc saw 60.80% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AGIO starting from Scadden David, who sale 200 shares at the price of $46.28 back on Dec 11 ’24. After this action, Scadden David now owns 15,483 shares of Agios Pharmaceuticals Inc, valued at $9,256 using the latest closing price.
Washburn Theodore James Jr., the Principal Accounting Officer of Agios Pharmaceuticals Inc, sale 772 shares at $56.09 during a trade that took place back on Nov 08 ’24, which means that Washburn Theodore James Jr. is holding 813 shares at $43,301 based on the most recent closing price.
Stock Fundamentals for AGIO
Current profitability levels for the company are sitting at:
- -12.38 for the present operating margin
- 0.76 for the gross margin
The net margin for Agios Pharmaceuticals Inc stands at 20.51. The total capital return value is set at -0.24. Equity return is now at value 53.65, with 48.18 for asset returns.
Currently, EBITDA for the company is -384.86 million with net debt to EBITDA at 0.48. When we switch over and look at the enterprise to sales, we see a ratio of 56.26. The receivables turnover for the company is 10.54for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.99.
Conclusion
To put it simply, Agios Pharmaceuticals Inc (AGIO) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
